To understand the regulation of macrophage-mediated ADCC, we used human B cell lymphoma coated with Rituximab as the tumor target and murine macrophages primed with IFNγ as the effectors. The gene discussed is IFNG; the disease is B-cell non-Hodgkin lymphoma.